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Introduction {#oby21145-sec-0005}
============

Overweight and obesity represent a considerable disease burden during pregnancy, with half of all women having a body mass index (BMI) of ≥25 kg/m^2^ on entering pregnancy [1](#oby21145-bib-0001){ref-type="ref"}, [2](#oby21145-bib-0002){ref-type="ref"}. The literature highlights the associations between maternal obesity and an increased risk of adverse outcomes for both women and their infants, all of which increase as maternal BMI increases [3](#oby21145-bib-0003){ref-type="ref"}, [4](#oby21145-bib-0004){ref-type="ref"}. Additionally, there is evidence of a persisting longer‐term health legacy, maternal obesity being associated with an increased risk of high infant birth weight [4](#oby21145-bib-0004){ref-type="ref"} and, in turn, subsequent obesity [5](#oby21145-bib-0005){ref-type="ref"}, [6](#oby21145-bib-0006){ref-type="ref"}.

The US Institute of Medicine has summarized the observational literature relating to maternal gestational weight gain, reporting average total weight gains between 10 and 15 kg [7](#oby21145-bib-0007){ref-type="ref"}. However, there was considerable interindividual variation with many women, particularly those with a BMI of ≥25 kg/m^2^, exceeding this average [7](#oby21145-bib-0007){ref-type="ref"}. Nevertheless, current recommendations suggest a weight gain of 7.0‐11.5 kg for women with a BMI of 25‐29.9 kg/m^2^ and 5.0‐9.0 kg for women with a BMI of 30 kg/m^2^ or more [7](#oby21145-bib-0007){ref-type="ref"}.

In nonpregnant individuals, there is a clear relationship between measured weight gain and adiposity gain. In contrast, gestational weight gain while used as a surrogate marker of adiposity [8](#oby21145-bib-0008){ref-type="ref"} in fact reflects a combination of maternal fat deposition, pregnancy‐related plasma volume expansion, peripheral edema, placental mass, fetal mass, and amniotic fluid volume [9](#oby21145-bib-0009){ref-type="ref"}. Furthermore, from a practical perspective, determining the relative contribution of each of these individual components is extremely difficult [9](#oby21145-bib-0009){ref-type="ref"}.

Although a number of techniques have been proposed to differentiate between the various components and more accurately determine maternal adiposity, all have limitations, particularly during pregnancy. Although BMI correlates well with the markers of adult health and disease risk, it does not differentiate between adipose and lean tissue mass or between maternal and fetal contributions to weight gain. Bioimpedance analysis, dual‐energy X‐ray absorptiometry, computed tomography, magnetic resonance imaging, and three or four compartment model assessments all more accurately determine adipose and lean tissues. Limitations include the lack of differentiation between maternal and fetal tissues, exposure to ionizing radiation [9](#oby21145-bib-0009){ref-type="ref"}, [10](#oby21145-bib-0010){ref-type="ref"}, and lack of portability and expense [9](#oby21145-bib-0009){ref-type="ref"}, [11](#oby21145-bib-0011){ref-type="ref"}, [12](#oby21145-bib-0012){ref-type="ref"}, all of which make these assessments impractical to carry out on a large scale.

In contrast, skinfold thickness measurements (SFTM) have been proposed for use in pregnancy as they are reproducible with specific training and adherence to defined protocols, and through the measurement of between three and seven body sites, they allow estimation of body fat (BF) percentage [9](#oby21145-bib-0009){ref-type="ref"}, [13](#oby21145-bib-0013){ref-type="ref"}. In particular, use of the biceps, triceps, and subscapular sites allows the evaluation of pregnancy‐related changes in adipose tissue that are more independent of fetal growth [9](#oby21145-bib-0009){ref-type="ref"}, [14](#oby21145-bib-0014){ref-type="ref"}. Although some have suggested that SFTM lack reproducibility [15](#oby21145-bib-0015){ref-type="ref"}, we have documented acceptable interobserver variability from a population of pregnant women with a BMI of ≥25 kg/m^2^ [16](#oby21145-bib-0016){ref-type="ref"}.

Observational studies involving lean pregnant women suggest deposition of adipose tissue in the second trimester of pregnancy with subsequent mobilization in late gestation [17](#oby21145-bib-0017){ref-type="ref"}, [18](#oby21145-bib-0018){ref-type="ref"}, [19](#oby21145-bib-0019){ref-type="ref"}, [20](#oby21145-bib-0020){ref-type="ref"}. It is unclear if this is also the case among women with a BMI of ≥25 kg/m^2^, who have increased reliance on lipid metabolism during pregnancy [21](#oby21145-bib-0021){ref-type="ref"}. Similarly, the relationship between changes in adipose tissue deposition and SFTM, particularly among women with a BMI of ≥25 kg/m^2^ [19](#oby21145-bib-0019){ref-type="ref"}, [22](#oby21145-bib-0022){ref-type="ref"}, and any correlation with either gestational weight gain or infant birth weight [23](#oby21145-bib-0023){ref-type="ref"}, [24](#oby21145-bib-0024){ref-type="ref"} remain to be determined.

We have reported the primary findings of the LIMIT randomized trial evaluating the provision of antenatal dietary and lifestyle advice to women with a BMI of ≥25 kg/m^2^, which indicate a significant 18% relative risk reduction in infant birth weight of \>4 kg [25](#oby21145-bib-0025){ref-type="ref"}, mediated by improvements in maternal diet and physical activity [26](#oby21145-bib-0026){ref-type="ref"}. The aims of this study were twofold. First, we report the effect of providing antenatal dietary and lifestyle advice on the measures of maternal SFTM; and second, we assess the correlation between maternal SFTM and both gestational weight gain and infant birth weight.

Methods {#oby21145-sec-0006}
=======

Study design {#oby21145-sec-0007}
------------

We conducted a multicenter, randomized trial involving three maternity hospitals across Adelaide, South Australia. The methods [27](#oby21145-bib-0027){ref-type="ref"} and primary findings [25](#oby21145-bib-0025){ref-type="ref"}, [26](#oby21145-bib-0026){ref-type="ref"}, [28](#oby21145-bib-0028){ref-type="ref"} from the LIMIT randomized trial have been reported, and the trial registered on the Australian and New Zealand Clinical Trials Registry (ACTRN12607000161426).

Inclusion and exclusion criteria {#oby21145-sec-0008}
--------------------------------

Women with BMI of ≥25 kg/m^2^ and singleton pregnancy at 10^+0^‐20^+0^ weeks gestation were eligible.

Trial entry {#oby21145-sec-0009}
-----------

All women presenting for antenatal care had their height and weight measured, and BMI calculated at the first antenatal appointment. Eligible women were presented with written information, and all women provided written informed consent.

Randomization, masking, and group allocation {#oby21145-sec-0010}
--------------------------------------------

Randomization occurred by telephoning the central randomization service, which used a computer‐generated schedule, with balanced variable blocks. Stratification occurred for parity (0 vs. 1/more), BMI at antenatal booking (25‐29.9 vs. ≥30 kg/m^2^), and collaborating center. Women were randomized to either "Lifestyle Advice" or "Standard Care."

Treatment schedules {#oby21145-sec-0011}
-------------------

### Lifestyle Advice Group {#oby21145-sec-0012}

Women randomized to receive Lifestyle Advice participated in a comprehensive dietary and lifestyle intervention over the course of pregnancy that included a combination of dietary, physical activity, and behavioral strategies, delivered by a research dietician and trained research assistants [25](#oby21145-bib-0025){ref-type="ref"}, [26](#oby21145-bib-0026){ref-type="ref"}. Within 2 weeks of randomization, women attended a planning session with a research dietician, during which a detailed dietary and physical activity history was obtained [25](#oby21145-bib-0025){ref-type="ref"}, [26](#oby21145-bib-0026){ref-type="ref"}. Women were provided with individualized dietary advice consistent with current Australian standards, to maintain a balance of carbohydrates, fat, and protein, to reduce intake of foods high in refined carbohydrates and saturated fats, while increasing intake of fiber, and promoting consumption of two servings of fruit, five servings of vegetables, and three servings of dairy each day. Physical activity advice focussed on the benefits of exercise in pregnancy, and tips to increase incidental activity and walking. Women were encouraged to set achievable goals for change, and to self‐monitor their progress. This information was reinforced during subsequent inputs provided by the research dietician (at 28‐week gestation) and trained research assistants (via telephone call at 22‐, 24‐, and 32‐week gestation and a face‐to‐face visit at 36‐week gestation).

### Standard Care Group {#oby21145-sec-0013}

Women receiving Standard Care continued their pregnancy care according to local hospital guidelines, which did not include routine provision of advice related to diet, exercise, or gestational weight gain.

Study end points: maternal anthropometry {#oby21145-sec-0014}
----------------------------------------

At trial entry and 36‐week gestation, maternal anthropometric measures were obtained [16](#oby21145-bib-0016){ref-type="ref"}, using a standardized protocol on the right‐hand side of the woman\'s body [13](#oby21145-bib-0013){ref-type="ref"}.

### Arm circumference {#oby21145-sec-0015}

With the woman standing with her arms relaxed at her side, the midpoint between the most superior and the lateral point of the acromion border and the most proximal and lateral border of the head of the radius was identified and the circumference measured using the crosshand technique, with the reading taken at eye level with constant tension applied to the tape [13](#oby21145-bib-0013){ref-type="ref"}, [16](#oby21145-bib-0016){ref-type="ref"}. Two separate marks were made on the woman\'s arm on the most anterior point of the biceps and the most posterior point of the triceps, to assist in locating these skinfold landmarks [13](#oby21145-bib-0013){ref-type="ref"}, [16](#oby21145-bib-0016){ref-type="ref"}.

### Skinfold thickness measurements {#oby21145-sec-0016}

SFTM were obtained using Harpenden Callipers, with a dial graduation of 0.2 mm and measuring range 0‐80 mm, which was viewed at 90° to avoid errors of parallax. Two measurements were taken, with a third measurement obtained if the difference was \>7.5% [13](#oby21145-bib-0013){ref-type="ref"}, [16](#oby21145-bib-0016){ref-type="ref"}. The measurements were recorded to the nearest 0.1 mm and reported as the average of two measurements or the median of 3 [13](#oby21145-bib-0013){ref-type="ref"}, [16](#oby21145-bib-0016){ref-type="ref"}.

#### Biceps {#oby21145-sec-0017}

With the woman standing relaxed, with arms at her side, the biceps skinfold was visualized, and the site located on the anterior surface of the arm, in line with the mid‐arm point (as marked when the arm circumference was measured) and parallel to the long axis [13](#oby21145-bib-0013){ref-type="ref"}, [16](#oby21145-bib-0016){ref-type="ref"}.

#### Triceps {#oby21145-sec-0018}

With the woman standing relaxed and her arm slightly pronated, the triceps skinfold was visualized from the posterior surface of the arm, in line with the mid‐arm point in the horizontal plane (as marked when the arm circumference was measured), and parallel to the long axis [13](#oby21145-bib-0013){ref-type="ref"}, [16](#oby21145-bib-0016){ref-type="ref"}.

#### Subscapular {#oby21145-sec-0019}

The inferior angle of the scapula was palpated, and a site marked 2 cm and 45° inferiorly [13](#oby21145-bib-0013){ref-type="ref"}, [16](#oby21145-bib-0016){ref-type="ref"}. If required, the woman was asked to reach behind her back with her right arm to better expose the scapula [13](#oby21145-bib-0013){ref-type="ref"}, [16](#oby21145-bib-0016){ref-type="ref"}.

### BF percentage {#oby21145-sec-0020}

Using the following equation for use with pregnant women with a BMI of ≥25 kg/m^2^, percentage BF was calculated, where SFTM were reported in millimeters, and arm circumference and height were reported in centimeters [16](#oby21145-bib-0016){ref-type="ref"}.

BF% = 12.7 + 0.457 (Triceps SFTM) + 0.352 (Subscapular SFTM) + 0.103 (Biceps SFTM) − 0.057 (Height) + 0.265 (Arm circumference).

### Gestational weight gain {#oby21145-sec-0021}

Gestational weight gain was calculated as the difference in measured weight by subtracting the weight obtained at trial entry from the weight obtained at 36 weeks of gestation. Weight was obtained with the woman in light clothing and without shoes, using digital scales, and recorded to the nearest 0.1 kg. Height was obtained without shoes, using a wall‐mounted stadiometer, and recorded to the nearest 0.5 cm.

Analysis and reporting of results {#oby21145-sec-0022}
---------------------------------

The analyses were performed on an intention to treat basis, with women analyzed according to their randomized treatment group. Women were included in the analysis if they consented to anthropometric measurements being taken, and did not withdraw consent to use their data or have a miscarriage, or termination of pregnancy. The outcomes considered were the anthropometric measurements taken at 36‐week gestation, and both the total and the average weekly change in anthropometric measurements between trial entry and 36 weeks. The analyses were performed using linear regression models to determine the effect of treatment group on each outcome, adjusting for center, parity, BMI category, age, socioeconomic status, the anthropometric measurement at trial entry, and either the actual gestational age at measurement (for anthropometric measurements at 36 weeks), or the time between measurements (for changes in anthropometric measurements). Exploratory analyses were conducted to assess whether the effect of treatment varied by BMI category (overweight vs. obese), by including an interaction between treatment group and BMI category in the regression model. Statistical significance was assessed at the two‐sided *P* \< 0.05 level and no adjustment was made for multiple comparisons. Pearson\'s correlation coefficients were calculated to measure the strength of association between anthropometric measurements, total gestational weight gain, and infant birth weight. All analyses were performed using SAS v9.3 (Cary, NC, USA).

Sample size {#oby21145-sec-0023}
-----------

The sample size of 2,180 women was predetermined based on the primary outcome, large for gestational age infant [25](#oby21145-bib-0025){ref-type="ref"}.

Ethics {#oby21145-sec-0024}
------

Ethics approval was provided by the Women\'s and Children\'s Local Health Network Human Research and Ethics Committee at the Women\'s and Children\'s Hospital, the Central Northern Adelaide Health Service Ethics of Human Research Committee (Lyell McEwin Hospital) and the Flinders Clinical Research Ethics Committee (Flinders Medical Centre).

Results {#oby21145-sec-0025}
=======

Between June 2008 and December 2011, 2,212 women were randomized, with 1,108 allocated to receive Lifestyle Advice, and 1,104 Standard Care. There were 2,154 women (1,080 Lifestyle Advice; 1,072 Standard Care) available for inclusion in the analyses, after excluding women who withdrew consent to use their data (ten women) or had a miscarriage, or termination of pregnancy (50 women) [25](#oby21145-bib-0025){ref-type="ref"}. The measurements were obtained from 872 (80.7%) women at trial entry, and 807 (74.7%) at 36 weeks of gestation in the Lifestyle Advice Group, and 835 (77.9%) women at trial entry, and 775 (72.3%) at 36 weeks of gestation in the Standard Care Group, who were included in the analyses (Figure [1](#oby21145-fig-0001){ref-type="fig"}). The median time between trial entry and 36‐week gestation measurements was 18.4 weeks (interquartile range, 16.0‐21.6 weeks). Baseline demographic and anthropometric measures of the women who had their measurements obtained were similar between treatment groups (Table [1](#oby21145-tbl-0001){ref-type="table-wrap"}) and their clinical characteristics similar to the full randomized groups (data not shown) [25](#oby21145-bib-0025){ref-type="ref"}.

![Flow of participants.](OBY-23-1555-g001){#oby21145-fig-0001}

###### 

Baseline demographic and anthropometric measurements at trial entry

  Characteristic                                                                   Lifestyle Advice, *N* = 872[a](#oby21145-note-0003){ref-type="fn"}   Standard Care, *N* = 835[a](#oby21145-note-0003){ref-type="fn"}   Total, *N* = 1,707[a](#oby21145-note-0003){ref-type="fn"}
  -------------------------------------------------------------------------------- -------------------------------------------------------------------- ----------------------------------------------------------------- -----------------------------------------------------------
  Maternal age (years)[b](#oby21145-note-0004){ref-type="fn"}                      29.6 (5.3)                                                           29.6 (5.5)                                                        29.6 (5.4)
  Gestational age at entry (weeks)[c](#oby21145-note-0005){ref-type="fn"}          14.1 (12.0‐16.9)                                                     14.3 (12.0‐17.0)                                                  14.1 (12.0‐17.0)
  BMI (kg/m^2^)[c](#oby21145-note-0005){ref-type="fn"}                             31.0 (28.0‐35.9)                                                     31.1 (27.6‐35.8)                                                  31.0 (27.8‐35.8)
  *BMI category* [d](#oby21145-note-0006){ref-type="fn"}                                                                                                                                                                  
  25.0‐29.9                                                                        365 (41.9)                                                           360 (43.1)                                                        725 (42.5)
  30.0‐34.9                                                                        249 (28.6)                                                           238 (28.5)                                                        487 (28.5)
  35.0‐39.9                                                                        167 (19.2)                                                           135 (16.2)                                                        302 (17.7)
  ≥40.0                                                                            91 (10.4)                                                            102 (12.2)                                                        193 (11.3)
  Public patient[d](#oby21145-note-0006){ref-type="fn"}                            855 (98.1)                                                           814 (97.5)                                                        1669 (97.8)
  Weight (kg)[b](#oby21145-note-0004){ref-type="fn"}                               88.4 (17.0)                                                          88.3 (17.6)                                                       88.3 (17.3)
  Height (cm)[b](#oby21145-note-0004){ref-type="fn"}                               164.9 (6.6)                                                          164.9 (6.5)                                                       164.9 (6.5)
  Race[d](#oby21145-note-0006){ref-type="fn"}                                                                                                                                                                             
  Caucasian                                                                        789 (90.5)                                                           764 (91.5)                                                        1553 (91.0)
  Asian                                                                            19 (2.2)                                                             21 (2.5)                                                          40 (2.3)
  Indian                                                                           30 (3.4)                                                             27 (3.2)                                                          57 (3.3)
  Other                                                                            34 (3.9)                                                             23 (2.8)                                                          57 (3.3)
  Smoker[d](#oby21145-note-0006){ref-type="fn"}                                    110 (12.6)                                                           93 (11.1)                                                         203 (11.9)
  Nulliparous[d](#oby21145-note-0006){ref-type="fn"}                               354 (40.6)                                                           358 (42.9)                                                        712 (41.7)
  *Index of socio economic disadvantage* [e](#oby21145-note-0007){ref-type="fn"}                                                                                                                                          
  Unknown                                                                          1 (0.1)                                                              1 (0.1)                                                           2 (0.1)
  Quintile 1 (most disadvantaged)                                                  262 (30.0)                                                           240 (28.7)                                                        502 (29.4)
  Quintile 2                                                                       207 (23.7)                                                           212 (25.4)                                                        419 (24.5)
  Quintile 3                                                                       133 (15.3)                                                           125 (15.0)                                                        258 (15.1)
  Quintile 4                                                                       126 (14.4)                                                           133 (15.9)                                                        259 (15.2)
  Quintile 5 (least disadvantaged)                                                 143 (16.4)                                                           124 (14.9)                                                        267 (15.6)
  Arm girth at trial entry (cm)[b](#oby21145-note-0004){ref-type="fn"}             35.5 (4.4)                                                           35.4 (4.4)                                                        35.5 (4.4)
  Biceps SFTM at trial entry (mm)[b](#oby21145-note-0004){ref-type="fn"}           18.2 (7.5)                                                           17.4 (6.9)                                                        17.8 (7.2)
  Triceps SFTM at trial entry (mm)[b](#oby21145-note-0004){ref-type="fn"}          27.8 (7.3)                                                           28.4 (7.4)                                                        28.1 (7.4)
  Subscapular SFTM at trial entry (mm)[b](#oby21145-note-0004){ref-type="fn"}      28.8 (9.1)                                                           29.4 (9.7)                                                        29.1 (9.4)
  Percent BF at trial entry[b](#oby21145-note-0004){ref-type="fn"}                 37.4 (7.2)                                                           37.7 (7.5)                                                        37.6 (7.3)
  GA at trial entry measurement (weeks)[c](#oby21145-note-0005){ref-type="fn"}     17.0 (14.3‐19.9)                                                     18.9 (14.9‐20.4)                                                  17.6 (14.6‐20.3)

Includes all women randomized who did not withdraw consent to use their data and who had anthropometric measurements taken at baseline.

Mean and standard deviation.

Median and interquartile range.

Number and percentage.

Socio economic index as measured by SEIFA.

There were no statistically significant differences between those women receiving Lifestyle Advice and those receiving Standard Care, with regards to arm circumference, and biceps, triceps, and subscapular SFTM obtained at 36‐week gestation (Table [2](#oby21145-tbl-0002){ref-type="table-wrap"}). There was no difference observed between groups in the change in these measurements from baseline to 36 weeks, when expressed either as total change, or as an average weekly change to account for variation in gestational age at measurement. The calculated percentage BF at 36‐week gestation did not significantly differ between the two treatment groups (37.66 ± 7.12% Lifestyle Advice vs. 37.25 ± 7.02% Standard Care; adjusted mean difference 0.48; 95% CI −0.01 to 1.00; *P* = 0.07), with no difference observed in the change in percentage BF expressed either as total change across gestation, or as average weekly change. There was no evidence to suggest that the intervention effect was modified by maternal BMI category (data not shown).

###### 

Maternal anthropometric outcomes by treatment group[a](#oby21145-note-0008){ref-type="fn"}

  Outcome                                              Lifestyle Advice Group   Standard Care Group   Unadjusted treatment effect (95% CI)   Unadjusted *P*‐value   Adjusted treatment effect (95% CI)   Adjusted *P*‐value
  ---------------------------------------------------- ------------------------ --------------------- -------------------------------------- ---------------------- ------------------------------------ --------------------
  Arm girth at 36 weeks (cm)                           35.61 (4.13)             35.47 (4.24)          0.14 (−0.27, 0.56)                     0.4909                 −0.03 (−0.19, 0.12)                  0.6709
  Total change in arm girth (cm)                       0.06 (1.66)              0.14 (1.61)           −0.08 (−0.25, 0.09)                    0.3474                 −0.03 (−0.19, 0.13)                  0.7188
  Average weekly change in arm girth (cm)              0.00 (0.09)              0.01 (0.09)           −0.00 (−0.01, 0.00)                    0.3199                 −0.00 (−0.01, 0.01)                  0.6952
  Biceps skinfold at 36 weeks (mm)                     16.32 (6.26)             15.95 (5.97)          0.38 (−0.23, 0.98)                     0.2230                 0.06 (−0.46, 0.58)                   0.8124
  Total change in biceps skinfold (mm)                 −1.88 (6.54)             −1.38 (6.55)          −0.50 (−1.17, 0.17)                    0.1409                 0.02 (−0.50, 0.55)                   0.9289
  Average weekly change in biceps skinfold (mm)        −0.10 (0.35)             −0.08 (0.36)          −0.03 (−0.06, 0.01)                    0.1356                 −0.00 (−0.03, 0.03)                  0.8673
  Triceps skinfold at 36 weeks (mm)                    27.91 (7.60)             27.44 (7.29)          0.48 (−0.26, 1.21)                     0.2032                 0.58 (−0.07, 1.23)                   0.0790
  Total change in triceps skinfold (mm)                −0.00 (7.71)             −0.83 (7.42)          0.83 (0.06, 1.61)                      0.0346                 0.53 (−0.13, 1.18)                   0.1149
  Average weekly change in triceps skinfold (mm)       −0.00 (0.42)             −0.05 (0.42)          0.05 (0.01, 0.09)                      0.0203                 0.03 (−0.00, 0.07)                   0.0806
  Subscapular skinfold at 36 weeks (mm)                29.91 (8.82)             29.66 (8.98)          0.25 (−0.63, 1.14)                     0.5773                 0.55 (−0.12, 1.23)                   0.1052
  Total change in subscapular skinfold (mm)            0.90 (7.74)              0.05 (7.24)           0.85 (0.07, 1.62)                      0.0325                 0.50 (−0.17, 1.18)                   0.1429
  Average weekly change in subscapular skinfold (mm)   0.05 (0.43)              −0.00 (0.42)          0.05 (0.01, 0.09)                      0.0290                 0.03 (−0.01, 0.07)                   0.1244
  Percent BF at 36 weeks                               37.66 (7.12)             37.25 (7.02)          0.40 (−0.30, 1.11)                     0.2619                 0.48 (−0.04, 1.00)                   0.0711
  Total change in percent BF                           0.12 (5.84)              −0.45 (5.65)          0.56 (−0.03, 1.16)                     0.0650                 0.43 (−0.09, 0.95)                   0.1082
  Average weekly change in percent BF                  0.00 (0.32)              −0.03 (0.32)          0.03 (0.00, 0.07)                      0.0448                 0.03 (−0.00, 0.06)                   0.0821

Values are mean (SD) and treatment effects are differences in means. Adjusted for center, parity, BMI category, age, socioeconomic status quintile, smoking status, baseline measurement, and either GA at measurement (for 36‐week measurement outcomes) or time between measurements (for total and average weekly change). Includes all women randomized who had anthropometric data collected, did not have a miscarriage or termination, and did not withdraw consent to use their data.

All SFTM and arm circumference measurements were not significantly correlated with either gestational weight gain or infant birth weight, correlation coefficients ranging between −0.239 and 0.111 (Table [3](#oby21145-tbl-0003){ref-type="table-wrap"}).

###### 

Correlations between maternal morphology measurements at trial entry and 36‐week gestation, gestational weight gain, and infant birth weight

                                         Pearson\'s correlation coefficients   
  -------------------------------------- ------------------------------------- --------
  Total gestational weight gain (kg)                                           0.223
  Arm girth at trial entry (cm)          −0.239                                0.046
  Arm girth at 36 weeks (cm)             0.002                                 0.087
  Biceps SFTM at trial entry (mm)        −0.185                                0.009
  Biceps SFTM at 36 weeks (mm)           0.070                                 0.055
  Triceps SFTM at trial entry (mm)       −0.159                                0.036
  Triceps SFTM at 36 weeks (mm)          0.111                                 0.107
  Subscapular SFTM at trial entry (mm)   −0.221                                −0.010
  Subscapular SFTM at 36 weeks (mm)      0.028                                 0.057
  Percentage BF at trial entry           −0.230                                0.007
  Percentage BF at 36 weeks              0.066                                 0.081

Discussion {#oby21145-sec-0026}
==========

Our randomized trial is the largest reported to date evaluating the effects of an antenatal lifestyle intervention for women with a BMI of ≥25 kg/m^2^ during pregnancy on maternal anthropometric measures, and it utilized robust methodology. Our findings indicate that providing an intervention during pregnancy was not effective in reducing gestational weight gain [25](#oby21145-bib-0025){ref-type="ref"} or maternal measures of peripheral adipose tissue deposition. Nor was there any effect on maternal percentage BF, with no evidence to suggest this differed among women with a BMI of 25--29.9 kg/m^2^ and ≥30 kg/m^2^. Furthermore, SFTM and anthropometric measures were not significantly correlated with either gestational weight gain or infant birth weight.

Our study has a number of strengths, including the large sample size of pregnant women with a BMI of ≥25 kg/m^2^, which has been a limitation of the literature to date. Although there are limitations to the use of skinfold measurements as an accurate predictor of adiposity, we adhered to a validated protocol, with acceptable reported interobserver variability [16](#oby21145-bib-0016){ref-type="ref"}, allowing comparisons between treatment groups to be made. Use of alternative methods of the assessment of maternal adiposity may have yielded more accurate estimates of the relative proportions of adipose and lean tissue mass although these were not considered feasible for use on such a large scale.

It is widely assumed that women deposit adipose tissue during pregnancy, with mobilization of peripheral stores as a fuel source for fetal growth in late gestation and during lactation [29](#oby21145-bib-0029){ref-type="ref"}. A number of observational studies suggest that there is maximal subcutaneous fat accumulation as measured by skinfold thickness, during the second trimester of pregnancy, followed by a decline in the third trimester as an indicator of tissue mobilization [17](#oby21145-bib-0017){ref-type="ref"}, [18](#oby21145-bib-0018){ref-type="ref"}, [19](#oby21145-bib-0019){ref-type="ref"}, [20](#oby21145-bib-0020){ref-type="ref"}. However, these studies have largely been confined to relatively lean pregnant women, with the mean reported early pregnancy BMI within the normal range [17](#oby21145-bib-0017){ref-type="ref"}, [18](#oby21145-bib-0018){ref-type="ref"}, [19](#oby21145-bib-0019){ref-type="ref"}, [20](#oby21145-bib-0020){ref-type="ref"}.

In contrast, description of the subcutaneous accumulation of fat stores across gestation among women with a BMI of ≥25 kg/m^2^ is less conclusive. Although some suggest that there is a decrease in the measures of subcutaneous adipose tissue over pregnancy [19](#oby21145-bib-0019){ref-type="ref"}, others have reported relative stability in SFTM, particularly involving the triceps and subscapular sites [22](#oby21145-bib-0022){ref-type="ref"}. However, changes in SFTM across pregnancy appear to be site specific, with increases in central adipose tissue deposition reported by some, as measured at the suprailiac, subscapular [30](#oby21145-bib-0030){ref-type="ref"}, and thigh skinfold sites [22](#oby21145-bib-0022){ref-type="ref"}. Importantly, there appears to be considerable interindividual variation, with pregnant women with high BMI reported to have a greater variation in the change in fat mass over time when compared with women of normal BMI [31](#oby21145-bib-0031){ref-type="ref"}, [32](#oby21145-bib-0032){ref-type="ref"}. Although we assessed upper body measures only, our findings are consistent with those reported by Sidebottom et al. [22](#oby21145-bib-0022){ref-type="ref"}, indicating relatively little change in SFTM and subcutaneous adipose tissue accumulation in the second and third trimesters of pregnancy. Additional assessment of maternal SFTM at 28 weeks of gestation may have allowed greater assessment of mobilization of peripheral adipose tissue stores during gestation although it was not considered feasible in the context of this study, where participant burden was considerable.

Although measured weight gain in nonpregnant individuals is more closely reflective of adiposity gain, measuring gestational weight gain in pregnancy is a relatively poor surrogate for maternal adiposity [8](#oby21145-bib-0008){ref-type="ref"}, highlighting the considerable variability which exists across individual women in the composition of that weight gain [11](#oby21145-bib-0011){ref-type="ref"}, [12](#oby21145-bib-0012){ref-type="ref"}. Among relatively lean pregnant women, subcutaneous measures of adipose tissue deposition have been demonstrated to correlate poorly with gestational weight gain [14](#oby21145-bib-0014){ref-type="ref"}, [22](#oby21145-bib-0022){ref-type="ref"} although this observation is not universal, with others suggesting a positive association [32](#oby21145-bib-0032){ref-type="ref"}, [33](#oby21145-bib-0033){ref-type="ref"}. Furthermore, measured gains in maternal adipose tissue appear to be poorly predictive of infant birth weight [32](#oby21145-bib-0032){ref-type="ref"}, [33](#oby21145-bib-0033){ref-type="ref"}, [34](#oby21145-bib-0034){ref-type="ref"}, conferring little advantage over traditional assessment of prepregnancy or early pregnancy BMI [14](#oby21145-bib-0014){ref-type="ref"}, [20](#oby21145-bib-0020){ref-type="ref"}, perhaps with the exception of women with low prepregnancy weight, where there appears to be a negative correlation with low infant birth weight [35](#oby21145-bib-0035){ref-type="ref"}, [36](#oby21145-bib-0036){ref-type="ref"}.

To date, associations between measured maternal adiposity, gestational weight gain, and infant birth weight among women with a BMI of ≥25 kg/m^2^ have been poorly investigated. Although observational data indicate women with obesity have greater gain in central adiposity (compared with women of normal BMI), there is poor correlation with infant birth weight [23](#oby21145-bib-0023){ref-type="ref"}, [24](#oby21145-bib-0024){ref-type="ref"}. These findings are consistent with ours. From a metabolic perspective, changes which occur during pregnancy are highly complex as it is their relationship to maternal BMI, adiposity gain, gestational weight gain, and infant birth weight. It is therefore not surprising that although these measures may be associated with each other, changes in one may not necessarily correspond to observable or measurable changes in another.

As we have reported previously, providing antenatal lifestyle advice among women with a BMI of ≥25 kg/m^2^ was associated with an 18% relative risk reduction in infant birth weight of \>4 kg [25](#oby21145-bib-0025){ref-type="ref"}, an effect mediated by changes in maternal diet quality and physical activity [26](#oby21145-bib-0026){ref-type="ref"} despite the fact that both maternal gestational weight gain [25](#oby21145-bib-0025){ref-type="ref"} and total energy intake during pregnancy [26](#oby21145-bib-0026){ref-type="ref"} did not differ significantly between the randomized groups. Our intervention consisted of three face‐to‐face sessions and three telephone contacts over the course of pregnancy and was of similar intensity to those utilized in the previously published studies [37](#oby21145-bib-0037){ref-type="ref"}, [38](#oby21145-bib-0038){ref-type="ref"}, [39](#oby21145-bib-0039){ref-type="ref"}. Although increasing the intensity of the intervention may have been associated with greater effects on maternal gestational weight gain and, in turn, maternal SFTM, it was not considered feasible to implement within current maternity care models. Furthermore, our findings suggest that focusing attention solely on gestational weight gain, rather than achievable, albeit modest changes in dietary intake and physical activity, may reduce important opportunities to significantly impact clinically relevant infant outcomes [25](#oby21145-bib-0025){ref-type="ref"}, [28](#oby21145-bib-0028){ref-type="ref"}.

Conclusion {#oby21145-sec-0027}
==========

As indicated previously, the use of gestational weight gain is a surrogate measure of maternal adiposity [8](#oby21145-bib-0008){ref-type="ref"}, [9](#oby21145-bib-0009){ref-type="ref"}. Although both gestational weight gain and maternal adiposity as assessed by peripheral SFTM are relatively simple measures to obtain, they were not impacted by our antenatal lifestyle intervention. Furthermore, among women with a BMI of ≥25 kg/m^2^, maternal SFTM and measures of anthropometry correlated poorly with both gestational weight gain and infant birth weight. Further mechanistic information is required to elucidate the specific changes in maternal metabolic pathways over the course of pregnancy and their relationship, if any, to peripheral measures of adiposity.
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